GLUT1DS1 Clinical Trial
Official title:
Compatibility of Triheptanoin (C7) With the Ketogenic Diet in Patients Diagnosed With Glucose Transporter Type 1 Deficiency
To explore triheptanoin (C7 oil) compatibility with the ketogenic diet by evaluating EEG, and seizure rate, glycemia and ketosis in proven G1D patients receiving a ketogenic diet.
This is a single site, open label proof of principle exploratory trial to investigate the compatibility of C7 oil with the ketogenic diet in subjects diagnosed with G1D. The ketogenic diet will have been previously described by the patient's treating physician independently of this study and for clinical reasons. The ketogenic diet supplies over 50% of calories from fat, subjects, who are already tolerating over this much fat as part of their previously prescribed ketogenic diet, will replace 45% of their daily caloric intake with the triheptanoin for 24 hours, during a 48 hour inpatient stay. Subjects will have a continuous EEG to monitor for any potential C7 related changes in seizure before, during, and after triheptanoin oil ingestion. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04112862 -
Sodium Lactate Infusion in GLUT1DS Patients
|
Early Phase 1 | |
| Active, not recruiting |
NCT04137692 -
Red Blood Cell Exchange Transfusion as a Novel Treatment for GLUT1 Deficiency Syndrome
|
N/A | |
| Completed |
NCT03041363 -
Treatment Development of Triheptanoin (G1D)
|
Phase 1 | |
| Recruiting |
NCT05234411 -
Ketonemia Through Menstrual Cycle
|
||
| Active, not recruiting |
NCT05887739 -
Harmonic Ratio in Patients With GLUT1 Deficiency Syndrome
|
||
| Active, not recruiting |
NCT04646850 -
Long-term Treatment With the Ketogenic Diet in Epilepsy
|
||
| Active, not recruiting |
NCT03181399 -
Diet Treatment Glucose Transporter Type 1 Deficiency (G1D)
|
Phase 2 |